|
Ridogrel
drug data and news
Ridogrel drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
| Generic name |
Ridogrel
|
| Brand Names/Synonyms |
RIDOGREL; Ridogrel [Usan:Ban:Inn]; Ridogrelum [Inn-Latin] |
| Indication |
Used as an adjunctive therapy to induce thrombolysis in patients suffering acute myocardial infarction. |
|
Sponsored links
|
|
Description |
Not Available |
| Pharmacology |
This drug is used with streptokinase as an adjunctive therapy to reduce the formation and size of blood clots. Blood clots can cause ischemic cardiac events (heart attacks). Ridorgel has the dual property of inhibiting the synthesis of thromboxane and blocking the receptors of thromboxane/prostaglandin/endoperoxides. It has been shown to accelerate the speed of recanalization and to delay or prevent reocclusion during systemic thrombolysis with tissue plasminogen activator (streptokinase). |
| Mechanism Of Action |
Ridogrel inhibits thromboxane A2 synthase and also blocks the thromboxane A2/prostaglandin endoperoxide receptors. It is a more potent antiplatelet agent than aspirin and might offer an advantage over aspirin as an adjunct to thrombolysis in patients suffering from acute myocardial infarction. |
Ridogrel News
(When available) |
[an error occurred while processing this directive] |
| Dosage Forms |
TABLETS |
| Drug_Category |
Thrombolytic agents |
| Absorption |
Rapidly absorbed after oral administration (30-60 min) |
| Interactions |
Not Available |
| Toxicity |
Not Available |
| Organisms Affected |
Humans and other mammals |
| Chemical IUPAC Name |
5-[pyridin-3-yl-[3-(trifluoromethyl)phenyl]-methylidene]aminooxypentanoic acid |
| Chemical Formula |
C18H17F3N2O3 |
| Molecular Weight |
366.334 g/mol |
| Smiles String |
C1=CC(=CC(=C1)C(F)(F)F)C(=NOCCCCC(=O)O)C2=CN=CC=C2 |
| Melting Point |
Not Available |
| Water Solubility |
Not Available |
| State |
Solid |
| LogP/Hphobicity |
Not Available |
| Isoelectric Point |
Not Available |
| Biotransformation |
Not Available |
| Half Life |
6-9 hours |
| Protein Binding [%] |
~60% bound-plasma proteins |
| RxList Link |
Not Available>RXlist |
|
Sponsored links
|
|
| Drug Reference |
Not Available |
| Drug Type |
Approved Drug |
| Accession No |
APRD00271 |
| CAS Registry Number |
110140-89-1 |
| KEGG Compound ID |
Not Available |
| PubChem ID |
SID:196719 |
| PharmGKB ID |
Not Available |
| SwissProt ID |
Not Available |
| GenBank ID |
Not Available |
| Drug ID Number [DIN] |
Not Available
|
|
|
